funnydoggy wrote: » So asymptomatic cases don't really spread?
FutureTeashock wrote: » You can have the one I won't be taking.
UAE Health Ministry conducts 103,199 additional #COVID19 tests in past 24 hours, announces 1,083 new cases, 970 recoveries
scouserstation wrote: » I see Johnson & Johnson are at the final stages of testing their Covid 19 vaccine, it seem to differ from the moderna vaccine in how it works, it doesn't seem to contain the mRNA mechanism that moderna are using so in my view this would make it safer as an mRNA vaccine has never been rolled out before
Hmmzis wrote: » It's a press release, so take the numbers with caution, but a 50-60% improvement rate would be hard to 'massage' with that n:https://www.biospace.com/article/releases/oncoimmune-s-saccovid-cd24fc-exhibits-superb-therapeutic-efficacy-a-potential-breakthrough-in-treating-severe-and-critical-covid-19/ The question I have is why they didn't complete enrollment? Did the ethics board tell them to stop giving placebo? This did happen with Remdesivir with far less impressive numbers.
ACitizenErased wrote: » 72% of patients improved with only 203 enrollments, I assume it met their criteria?
Le Bruise wrote: » So widespread use of this could cut the IFR of COVID by at least half if not two-thirds? Or am I reading it wrong?
Hmmzis wrote: » Taking the numbers at face value it would look that way.
Le Bruise wrote: » That's excellent news, could really take the sting out of this things tail.
Gael23 wrote: » Would a treatment take as long as a vaccine to be approved for mass administration?
mean gene wrote: » any update on rtes top story of few days ago some blocker thats a game changer no other media running with ithttps://www.rte.ie/news/2020/0922/1166648-covid-19-drug/
Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has initiated its first Phase 3 study to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. The trial is being conducted in the United Kingdom (UK), in partnership with the UK Government’s Vaccines Taskforce, and is expected to enroll and immunize up to 10,000 individuals between 18-84 (inclusive) years of age, with and without relevant comorbidities, over the next four to six weeks. “With a high level of SARS-CoV-2 transmission observed and expected to continue in the UK, we are optimistic that this pivotal Phase 3 clinical trial will enroll quickly and provide a near-term view of NVX-CoV2373’s efficacy,” said Gregory M. Glenn, M.D., President, Research and Development at Novavax. “The data from this trial is expected to support regulatory submissions for licensure in the UK, EU and other countries. We are grateful for the support of the UK Government, including from its Department of Health and Social Care and National Institute for Health Research, to advance this important research.” NVX-CoV2373 is a stable, prefusion protein made using Novavax’ recombinant protein nanoparticle technology that includes Novavax’ proprietary MatrixM™ adjuvant. The vaccine has a favorable product profile that will allow handling in an unfrozen, liquid formulation that can be stored at 2°C to 8°C, allowing for distribution using standard vaccine channels. Novavax has continued to scale-up its manufacturing capacity, currently at up to 2 billion annualized doses, once all capacity has been brought online by mid-2021. About the Phase 3 Study Consistent with its long-standing commitment to transparency and in order to enhance information-sharing during the worldwide pandemic, Novavax will be publishing its UK study protocol in the coming days. The UK Phase 3 clinical trial is a randomized, placebo-controlled, observer-blinded study to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373 with Matrix-M in up to 10,000 subjects aged 18 to 84 years. Half the participants will receive two intramuscular injections of vaccine comprising 5 µg of protein antigen with 50 µg Matrix‑M adjuvant, administered 21 days apart, while half of the trial participants will receive placebo. The trial is designed to enroll at least 25 percent of participants over the age of 65 as well as to prioritize groups that are most affected by COVID-19, including racial and ethnic minorities. Additionally, up to 400 participants will also receive a licensed seasonal influenza vaccine as part of a co-administration sub-study. The trial has two primary endpoints. The first primary endpoint is first occurrence of PCR-confirmed symptomatic COVID-19 with onset at least 7 days after the second study vaccination in volunteers who have not been previously infected with SARS-CoV-2. The second primary endpoint is first occurrence of PCR-confirmed symptomatic moderate or severe COVID-19 with onset at least 7 days after the second study vaccination in volunteers who have not been previously infected with SARS-CoV-2. The primary efficacy analysis will be an event-driven analysis based on the number of participants with symptomatic or moderate/severe COVID-19 disease. An interim analysis will be performed when 67% of the desired number of these cases has been reached. For further information, including media-ready images, b-roll, downloadable resources and more, click here. About NVX-CoV2373 NVXCoV2373 is a vaccine candidate engineered from the genetic sequence of SARSCoV2, the virus that causes COVID-19 disease. NVXCoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and contains Novavax’ patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigens and cannot replicate, nor can it cause COVID-19. In preclinical trials, NVXCoV2373 demonstrated indication of antibodies that block binding of spike protein to receptors targeted by the virus, a critical aspect for effective vaccine protection. In its the Phase 1 portion of its Phase 1/2 clinical trial, NVXCoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera. NVX-CoV2373 is also being evaluated in two ongoing Phase 2 studies, which began in August; a Phase 2b trial in South Africa, and a Phase 1/2 continuation in the U.S. and Australia. Novavax has secured $2 billion in funding for its global coronavirus vaccine program, including up to $388 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI).
hmmm wrote: » https://www.reuters.com/article/us-health-coronavirus-lufthansa-testing-idUSKCN26D2Z0 " airline trade group IATA on Tuesday touted antigen tests that can be processed on site and typically give results within about 15 minutes."
ACitizenErased wrote: » And another one: US biotech firm Novavax said Thursday it was initiating its final Phase 3 clinical trial for its experimental Covid-19 vaccine. The trial will be carried out in the United Kingdom and aims to enroll 10,000 volunteers, aged 18-84, with and without underlying conditions, over the next four to six weeks.https://www.france24.com/en/20200924-novavax-enters-late-stage-clinical-trials
funnydoggy wrote: » So many people are unbelievably pessimistic about a vaccine. "IF a vaccine is made" "Takes years" "We've never had one for a coronavirus" Why don't they spend 5 minutes reading about it instead of repeating the same tropes constantly?
Le Bruise wrote: » That's great. Always thought this was another way of getting back to a semblance of normality for travel/concerts/festivals etc. Do these quick tests tend to give a high percentage of false positives, or would they be fairly accurate?
mandrake04 wrote: » They are less sensitive and rely on the body being in an advanced state of infection, they produce higher percentage of false negatives compared to Molecular test.
